Arvinas (ARVN) Common Equity (2017 - 2026)
Arvinas (ARVN) recorded quarterly Common Equity of $386.8 million in Q1 2026, down 10.86% quarter-over-quarter from $433.9 million in Q4 2025, and down 41.4% on a YoY basis from $660.1 million in Q1 2025.
Arvinas (ARVN) Common Equity (2017 - 2026) Analysis & Trends
Arvinas' Common Equity history runs 10 years deep, the most recent figure standing at $386.8 million for Q1 2026.
- In Q1 2026, Common Equity fell 41.4% year-over-year to $386.8 million; the TTM figure through Mar 2026 stood at $386.8 million (down 41.4% YoY), while the FY2025 annual figure was $433.9 million, down 22.75% from the prior year.
- Common Equity was $386.8 million for Q1 2026 at Arvinas, down from $433.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $723.3 million in Q1 2022 to a low of $386.8 million in Q1 2026.
- Historically, Common Equity has averaged $569.7 million across 5 years, with a median of $586.0 million in 2024.
- The sharpest annual moves came in 2024 and 2026: Common Equity climbed 29.47% in 2024, then plunged 41.4% in 2026.
- A 5-year view of Common Equity shows it stood at $564.9 million in 2022, then rose by 16.83% to $660.0 million in 2023, then retreated by 14.89% to $561.7 million in 2024, then fell by 22.75% to $433.9 million in 2025, then dropped by 10.86% to $386.8 million in 2026.
- The last three Common Equity figures came in at $386.8 million (Q1 2026), $433.9 million (Q4 2025), and $564.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 386.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 386.80 Mn |
| Dec 31, 2025 | 433.90 Mn |
| Sep 30, 2025 | 564.40 Mn |
| Jun 30, 2025 | 609.30 Mn |
| Mar 31, 2025 | 660.10 Mn |
| Dec 31, 2024 | 561.70 Mn |
| Sep 30, 2024 | 586.00 Mn |
| Jun 30, 2024 | 600.20 Mn |
| Mar 31, 2024 | 609.70 Mn |
| Dec 31, 2023 | 660.00 Mn |
| Sep 30, 2023 | 457.20 Mn |
| Jun 30, 2023 | 463.60 Mn |
| Mar 31, 2023 | 511.00 Mn |
| Dec 31, 2022 | 564.90 Mn |
| Sep 30, 2022 | 621.50 Mn |
| Jun 30, 2022 | 670.60 Mn |
| Mar 31, 2022 | 723.30 Mn |
| Dec 31, 2021 | 781.70 Mn |
| Sep 30, 2021 | 817.70 Mn |
| Jun 30, 2021 | 582.90 Mn |